Treatment of sickle cell disease

Details Treatment of sickle cell disease Treatment of sickle cell disease

1995-08-18

1997-05-06

Henley, III, Raymond

Drug, bio-affecting and body treating compositions

Inorganic active ingredient containing

Heavy metal or compound thereof

424641, 424655, 424667, 424682, 424702, 4241951, 514 52, 514276, 514345, 514356, 514458, 514474, 514725, A61K 3332, A61K 3324, A61K 3336, A61K 3306, A61K 3304, A61K 3578, A61K 3170, A61K 3151, A61K 3144, A61K 31355, A61K 3134, A61K 3107

Patent

active

056268840

ABSTRACT:
A maintenance regimen with controlled intake of particular vitamin, mineral, and micronutrient formulations, drastically reduces the incidence and severity of sickle cell disease crises. The formulations include vitamin A, vitamin B-1, vitamin B-2, vitamin B-6, vitamin B-12, vitamin C, vitamin D, vitamin E, niacinamide, para-aminobenzoic acid (PABA), pantothenic acid, choline bitartrate, inositol, rutin, citrus bioflavonoid complex, betaine hydrochloride, hesperidin complex, folic acid, biotin, calcium, iron, magnesium, zinc, potassium, manganese, iodine, chromium, selenium, and a pharmaceutically acceptable carrier, provided at or just below critical saturation levels, determined for each individual by carefully monitoring tolerance on titration. The daily dose may exceed that necessary as dietary or nutritional supplements, and trigger an increase in the production of viable hemoglobin, and alters the overall blood profile. Platelet concentration is increased up to twice that of seen in normal blood, and the red blood cells produced display increased resistance to sickling. This enhanced biosynthesis is achieved by providing sufficient stores of precursors that stimulate low level manufacture without substantial feedback control by the upper central nervous system.

REFERENCES:
patent: 4261980 (1981-04-01), Cort
patent: 4376766 (1983-03-01), Collinson-Jones et al.
patent: 4629625 (1986-12-01), Gaull
patent: 4866052 (1989-09-01), Hider et al.
patent: 4904678 (1990-02-01), Chima
patent: 4945083 (1990-07-01), Jansen, Jr.
patent: 5108754 (1992-04-01), Wilburn
patent: 5114972 (1992-05-01), Ohnishi
patent: 5364644 (1994-11-01), Walaszek et al.
NIH Publication No. 89-2117, "Management and Therapy of Sickle Cell Disease," 1989, U.S. Department of Health and Human Services, Charache et al., ed.

Affiliated with

Also associated with

Rating

Treatment of sickle cell disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of sickle cell disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of sickle cell disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2130648